RGEN
VENTE TOTALE: 8 461 titres (~1 480 186,50 $ US)
- Insiders
- Loeillot Olivier
- Total bought
- —
- Total sold
- $1,480,186
- Last activity
- 2026-09-04
- Last synced
-
2026-09-10 10:26:50
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-10
RGEN presents a contradictory profile: exceptional liquidity (score 90) is offset by deeply depressed fundamentals (score 45) with margins well below historical averages and a ROIC of only ~1.6% against a P/E of ~190x…
The first sentence of the analysis written for RGEN on 2026-09-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 47.1% | 43.3% | 44.0% | 56.9% | 58.3% | |
| Ebit Margin | 11.6% | -1.0% | 9.4% | 27.5% | 24.6% | |
| Ebitda Margin | 22.3% | 12.7% | 23.0% | 34.6% | 30.3% | |
| Operating Profit Margin | 8.1% | -5.5% | 7.5% | 28.0% | 24.9% | |
| Pretax Profit Margin | 8.5% | -4.3% | 9.0% | 27.3% | 22.9% | |
| Continuous Operations Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Net Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Bottom Line Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Current Ratio | 8.374 | 8.408 | 6.738 | 2.469 | 2.483 | |
| Quick Ratio | 7.119 | 7.281 | 5.511 | 1.880 | 1.991 | |
| Solvency Ratio | 0.151 | 0.071 | 0.140 | 0.391 | 0.274 | |
| Cash Ratio | 4.167 | 5.973 | 4.555 | 1.295 | 1.609 | |
| Price To Earnings Ratio | 188.345 | -312.913 | 280.938 | 50.540 | 113.665 | |
| Price To Earnings Growth Ratio | -0.651 | 1.821 | -3.473 | 1.154 | 1.089 | |
| Forward Price To Earnings Growth Ratio | -0.651 | 1.821 | -3.473 | 1.154 | 1.089 | |
| Price To Earnings Diluted Ratio | 190.535 | -312.913 | 285.397 | 52.256 | 118.232 | |
| Price To Earnings Diluted Growth Ratio | -0.664 | 1.809 | -3.543 | 1.171 | 1.161 | |
| Price To Book Ratio | 4.375 | 4.081 | 5.099 | 4.914 | 8.325 | |
| Price To Sales Ratio | 12.481 | 12.691 | 15.843 | 11.715 | 21.729 | |
| Price To Free Cash Flow Ratio | 98.133 | 56.507 | 133.704 | 242.402 | 280.590 | |
| Price To Operating Cash Flow Ratio | 78.477 | 45.906 | 87.944 | 54.566 | 122.422 | |
| Debt To Assets Ratio | 0.234 | 0.243 | 0.251 | 0.167 | 0.155 | |
| Debt To Equity Ratio | 0.328 | 0.348 | 0.362 | 0.221 | 0.209 | |
| Debt To Capital Ratio | 0.247 | 0.258 | 0.266 | 0.181 | 0.173 | |
| Long Term Debt To Capital Ratio | 0.205 | 0.210 | 0.206 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.401 | 1.434 | 1.441 | 1.325 | 1.348 | |
| Working Capital Turnover Ratio | 0.761 | 0.673 | 0.821 | 1.394 | 1.177 | |
| Operating Cash Flow Ratio | 0.864 | 1.383 | 0.691 | 0.426 | 0.317 | |
| Operating Cash Flow Sales Ratio | 0.159 | 0.276 | 0.180 | 0.215 | 0.177 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.800 | 0.812 | 0.658 | 0.225 | 0.436 | |
| Debt Service Coverage Ratio | 3.371 | 3.623 | 1.563 | 0.849 | 0.664 | |
| Interest Coverage Ratio | 2.571 | -1.556 | 4.758 | 75.469 | 13.155 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.446 | 0.000 | 1.640 | 0.605 | 0.466 | |
| Operating Cash Flow Coverage Ratio | 0.170 | 0.256 | 0.160 | 0.407 | 0.325 | |
| Capital Expenditure Coverage Ratio | 4.992 | 5.330 | 2.922 | 1.290 | 1.774 | |
| Dividend Paid And Capex Coverage Ratio | 4.992 | 5.330 | 2.922 | 1.290 | 1.774 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 56.837 | 99.435 | 68.667 | 33.498 | 70.510 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 47.1% | ▲3.8% | ▼-2.8% |
| Ebit Margin | 11.6% | ▲12.6% | ▼-2.8% |
| Ebitda Margin | 22.3% | ▲9.6% | ▼-2.3% |
| Operating Profit Margin | 8.1% | ▲13.6% | ▼-4.5% |
| Pretax Profit Margin | 8.5% | ▲12.7% | ▼-4.2% |
| Continuous Operations Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Net Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Bottom Line Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Current Ratio | 8.374 | ▼-0.034 | ▲2.679 |
| Quick Ratio | 7.119 | ▼-0.162 | ▲2.363 |
| Solvency Ratio | 0.151 | ▲0.080 | ▼-0.054 |
| Cash Ratio | 4.167 | ▼-1.806 | ▲0.647 |
| Price To Earnings Ratio | 188.345 | ▲501.258 | ▲124.230 |
| Price To Earnings Growth Ratio | -0.651 | ▼-2.472 | ▼-0.639 |
| Forward Price To Earnings Growth Ratio | -0.651 | ▼-2.472 | ▼-0.639 |
| Price To Earnings Diluted Ratio | 190.535 | ▲503.448 | ▲123.834 |
| Price To Earnings Diluted Growth Ratio | -0.664 | ▼-2.473 | ▼-0.651 |
| Price To Book Ratio | 4.375 | ▲0.294 | ▼-0.984 |
| Price To Sales Ratio | 12.481 | ▼-0.209 | ▼-2.410 |
| Price To Free Cash Flow Ratio | 98.133 | ▲41.627 | ▼-64.134 |
| Price To Operating Cash Flow Ratio | 78.477 | ▲32.571 | ▲0.614 |
| Debt To Assets Ratio | 0.234 | ▼-0.009 | ▲0.024 |
| Debt To Equity Ratio | 0.328 | ▼-0.020 | ▲0.034 |
| Debt To Capital Ratio | 0.247 | ▼-0.011 | ▲0.022 |
| Long Term Debt To Capital Ratio | 0.205 | ▼-0.006 | ▲0.081 |
| Financial Leverage Ratio | 1.401 | ▼-0.034 | ▲0.011 |
| Working Capital Turnover Ratio | 0.761 | ▲0.088 | ▼-0.204 |
| Operating Cash Flow Ratio | 0.865 | ▼-0.519 | ▲0.128 |
| Operating Cash Flow Sales Ratio | 0.159 | ▼-0.117 | ▼-0.043 |
| Free Cash Flow Operating Cash Flow Ratio | 0.800 | ▼-0.013 | ▲0.213 |
| Debt Service Coverage Ratio | 3.372 | ▼-0.251 | ▲1.357 |
| Interest Coverage Ratio | 2.571 | ▲4.127 | ▼-16.308 |
| Short Term Operating Cash Flow Coverage Ratio | 5.446 | ▲5.446 | ▲3.815 |
| Operating Cash Flow Coverage Ratio | 0.170 | ▼-0.085 | ▼-0.093 |
| Capital Expenditure Coverage Ratio | 4.992 | ▼-0.338 | ▲1.731 |
| Dividend Paid And Capex Coverage Ratio | 4.992 | ▼-0.338 | ▲1.731 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 56.837 | ▼-42.598 | ▼-8.952 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $9.21B | $8.05B | $10.02B | $9.39B | $14.57B | |
| Enterprise value | $9.34B | $7.98B | $9.98B | $9.29B | $14.33B | |
| EV / Sales | 12.65x | 12.58x | 15.78x | 11.59x | 21.38x | |
| EV / Op. cash flow | 79.53x | 45.50x | 87.60x | 53.98x | 120.42x | |
| EV / Free cash flow | 99.45x | 56.01x | 133.18x | 239.81x | 276.01x | |
| EV / EBITDA | 56.84x | 99.44x | 68.67x | 33.50x | 70.51x | |
| Net debt / EBITDA | 0.75x | -0.89x | -0.27x | -0.36x | -1.17x | |
| Current ratio | 8.37x | 8.41x | 6.74x | 2.47x | 2.48x | |
| Income quality | 2.40x | -6.87x | 2.74x | 0.93x | 0.93x | |
| Graham number | $27 | — | $23 | $51 | $41 | |
| Graham net-net | $2 | $1 | $1 | $4 | $3 | |
| Tax burden | 78.4% | 94.4% | 62.8% | 84.9% | 83.6% | |
| Interest burden | 72.9% | 428.9% | 95.8% | 99.5% | 93.2% | |
| Working capital | $1.00B | $939.3M | $946.4M | $593.9M | $556.4M | |
| Invested capital | $2.81B | $2.70B | $2.66B | $2.13B | $1.98B | |
| Return on assets | 1.7% | -0.9% | 1.3% | 7.3% | 5.4% | |
| Operating ROA | 2.1% | -1.2% | 1.8% | 9.2% | 7.8% | |
| Return on tangible assets | 3.4% | -1.8% | 2.5% | 14.1% | 11.1% | |
| Return on equity | 2.3% | -1.3% | 1.8% | 9.7% | 7.3% | |
| Return on invested capital | 1.6% | -1.2% | 1.1% | 7.9% | 6.2% | |
| Return on capital employed | 2.1% | -1.3% | 1.8% | 10.6% | 8.4% | |
| Earnings yield | 0.5% | -0.3% | 0.4% | 2.0% | 0.9% | |
| Free cash flow yield | 1.0% | 1.8% | 0.7% | 0.4% | 0.4% | |
| Capex / Op. cash flow | 20.0% | 18.8% | 34.2% | 77.5% | 56.4% | |
| Capex / Depreciation | 24.3% | 38.0% | 57.3% | 233.9% | 174.5% | |
| Capex / Sales | 3.2% | 5.2% | 6.2% | 16.6% | 10.0% | |
| SG&A / Sales | 39.4% | 41.5% | 34.6% | 26.9% | 27.4% | |
| R&D / Sales | 7.3% | 6.8% | 6.8% | 5.5% | 5.1% | |
| Stock comp / Sales | 4.4% | 7.6% | 4.0% | 3.4% | 4.1% | |
| Intangibles / Total assets | 50.9% | 50.5% | 49.2% | 48.0% | 50.8% | |
| Days sales outstanding | 78d | 77d | 72d | 53d | 64d | |
| Days payables outstanding | 28d | 33d | 20d | 29d | 47d | |
| Operating cycle | 238d | 222d | 280d | 304d | 305d | |
| Cash conversion cycle | 210d | 190d | 260d | 275d | 258d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+14.4%EV / Sales ▲+0.6%EV / EBITDA ▼-42.8%EV / Op. cash flow ▲+34.032Earnings yield ▲+0.008
Profitability
Return on equity ▲+0.036Return on assets ▲+0.026Return on invested capital ▲+0.029Return on capital employed ▲+0.034Operating ROA ▲+0.033Income quality ▲+9.276Tax burden ▼-0.160
Efficiency
Days sales outstanding ▲+1.249Days payables outstanding ▼-4.558Operating cycle ▲+15.489Cash conversion cycle ▲+20.047Capex / Sales ▼-0.020R&D / Sales ▲+0.005
Balance-sheet strength
Current ratio ▼-0.034Net debt / EBITDA ▲+1.640Working capital ▲+62305000.000Invested capital ▲+107004000.000Intangibles / Total assets ▲+0.004
Change over 5 years
Valuation
Market cap ▼-36.8%EV / Sales ▼-40.8%EV / EBITDA ▼-19.4%EV / Op. cash flow ▼-40.892Earnings yield ▼-0.003Graham number ▼-13.786
Profitability
Return on equity ▼-0.050Return on assets ▼-0.038Return on invested capital ▼-0.046Return on capital employed ▼-0.063Operating ROA ▼-0.058Income quality ▲+1.474Tax burden ▼-0.052
Efficiency
Days sales outstanding ▲+14.490Days payables outstanding ▼-19.274Operating cycle ▼-67.358Cash conversion cycle ▼-48.084Capex / Sales ▼-0.068R&D / Sales ▲+0.022
Balance-sheet strength
Current ratio ▲+5.891Net debt / EBITDA ▲+1.924Working capital ▲+445144000.000Invested capital ▲+827692000.000Intangibles / Total assets ▲+0.001
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-29 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-29 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-07-21 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-16 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-10 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-04-06 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-09 Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- 2026-08-27 Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report? Repligen (RGEN) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-27 Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
- 2026-08-27 American Capital Management Inc. Makes New $49.26 Million Investment in Repligen Corporation $RGEN American Capital Management Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 361,055 shares of the biotechnology company''s stock, valued at approximately $49,262,000. Repligen comprises
- 2026-08-26 5 Biotech Stocks Worth Adding to Your Portfolio Now New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
- 2026-08-26 Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET.
- 2026-08-26 25,992 Shares in Repligen Corporation $RGEN Acquired by Bank of Nova Scotia Bank of Nova Scotia acquired a new stake in Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,992 shares of the biotechnology company''s stock, valued at approximately $3,547,000. Several other institutional investors have also modified their holdings
- 2026-08-25 Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here''s Who''s Best Positioned. On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
- 2026-08-22 B. Metzler seel. Sohn & Co. AG Takes $3.60 Million Position in Repligen Corporation $RGEN B. Metzler seel. Sohn and Co. AG acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 26,361 shares of the biotechnology company''s stock, valued at approximately $3,597,000. Several other institutional investors and hedge funds also
- 2026-08-01 Repligen Corporation $RGEN Shares Acquired by Avidity Partners Management LP Avidity Partners Management LP increased its position in shares of Repligen Corporation (NASDAQ: RGEN) by 54.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,800 shares of the biotechnology company''s stock after acquiring an additional 27,500